Multiple Sclerosis (MS) is an inflammatory disease that damages the nerves and affects the transfer of messages between the central nervous system and the rest of the body. It is progressively disabling, impairing mobility and quality of life.
MS is present in all regions of the world, being the estimated prevalence in Europe 108 per 100,000 inhabitants
In the European Union over 400,000 people have Multiple Sclerosis (MS)
54% of patients suffer some degree of spasticity during the first year since diagnosis
50% of people with MS have mobility noticeable affected and 15% already require walking aid in the first year of the disease
Within the first year after onset, 81% of patients reported some degree of unexplained fatigue
Minimal or mild cognitive impairment was noted by 50% of the patients within the first year with MS
The pain forces 30% of the patients to change some of their daily activities within the first year of the disease